| Literature DB >> 22470355 |
Aaron Y L Cheung1, Lindsay M Horvath, Laura Carrel, James Ellis.
Abstract
Rett syndrome (RTT) is a neurodevelopmental disorder that affects girls due primarily to heterozygous mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MECP2). Random X-chromosome inactivation (XCI) results in cellular mosaicism in which some cells express wild-type (WT) MECP2 while other cells express mutant MECP2. The generation of patient-specific human induced pluripotent stem cells (hiPSCs) facilitates the production of RTT-hiPSC-derived neurons in vitro to investigate disease mechanisms and identify novel drug treatments. The generation of RTT-hiPSCs has been reported by many laboratories, however, the XCI status of RTT-hiPSCs has been inconsistent. Some report RTT-hiPSCs retain the inactive X-chromosome (post-XCI) of the founder somatic cell allowing isogenic RTT-hiPSCs that express only the WT or mutant MECP2 allele to be isolated from the same patient. Post-XCI RTT-hiPSCs-derived neurons retain this allele-specific expression pattern of WT or mutant MECP2. Conversely, others report RTT-hiPSCs in which the inactive X-chromosome of the founder somatic cell reactivates (pre-XCI) upon reprogramming into RTT-hiPSCs. Pre-XCI RTT-hiPSC-derived neurons exhibit random XCI resulting in cellular mosaicism with respect to WT and mutant MECP2 expression. Here we review and attempt to interpret the inconsistencies in XCI status of RTT-hiPSCs generated to date by comparison to other pluripotent systems in vitro and in vivo and the methods used to analyze XCI. Finally, we discuss the relative strengths and weaknesses of post- and pre-XCI hiPSCs in the context of RTT, and other X-linked and autosomal disorders for translational medicine.Entities:
Keywords: Rett syndrome; X-chromosome inactivation; human induced pluripotent stem cells
Year: 2012 PMID: 22470355 PMCID: PMC3311266 DOI: 10.3389/fpsyt.2012.00024
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1Generation of pre- and post-XCI RTT-hiPSCs. RTT-hiPSCs have been generated from RTT-fibroblasts isolated from RTT patients who carry a heterozygous mutation in MECP2. The reprogramming of RTT-fibroblasts have yielded RTT-hiPSCs that are in a post-XCI (A) or pre-XCI (B) state. Post-XCI RTT-hiPSCs retains an Xi from the founder somatic cell and express MECP2 in a non-random monoallelic manner. This results in the generation of mutant and isogenic control RTT-hiPSCs depending on whether the Xi harbors the WT or mutant MECP2. The differentiation of post-XCI RTT-hiPSCs retains this XCI pattern allowing homogeneous cultures of neurons that express WT or mutant MECP2. Pre-XCI RTT-hiPSCs carry two Xa and express the WT and mutant MECP2 in a biallelic fashion. The differentiation of RTT-hiPSCs into neurons initiate random XCI resulting in a mosaic culture of neurons that either express WT or mutant MECP2. Mut, mutant.
Summary of RTT-fibroblasts reprogrammed, method of reprogramming, and the outcome of XCI status in RTT-hiPSCs.
| Group | Fibroblasts reprogrammed | Reprogramming method | Culture condition | XCI status of RTT-hiPSCs |
|---|---|---|---|---|
| Muotri (Marchetto et al., | GM11270 (R306C), GM11272 (1155del32), GM16548 (Q244X), GM17880 (T158M) | Retroviral ( | Feeder free – mTesr1 | Pre- and post-XCI |
| Ellis (Cheung et al., | △3–4 (Exon 3–4 delete), GM11270 (R306C), GM17880 (T158M) | Retroviral ( | bFGF/KOSR MEFs | Post-XCI |
| Renieri (Amenduni et al., | Retroviral ( | bFGF/KOSR MEFs | Post-XCI | |
| Park (Kim et al., | GM07928 (E235fs), GM11270 (R306C), GM16548 (Q244X), GM17567 (X487X), GM17880 (T158M) | Retroviral ( | bFGF/KOSR MEFs | Pre- and post-XCI |
| Colman (Pomp et al., | GM11272 (1155del32), GM17880 (T158M) | Retroviral ( | bFGF/KOSR MEFs | Post-XCI |
| Lentiviral ( | 2i + LIF | Pre-XCI | ||
| Chang (Ananiev et al., | GM17880 (T158M), GM07982 (V247X), GM11270 (R306C), RS0502 (R294X) | Retroviral ( | bFGF/KOSR MEFs | Post-XCI |
All fibroblasts reprogrammed are from female RTT-patients carrying a heterozygous mutation (indicated in parenthesis) in .
Summary of RTT-hiPSCs generated to date and their XCI status as determined by different methods.
| Group | Techniques used for XCI evaluation | XCI status of RTT-hiPSCs | ||||
|---|---|---|---|---|---|---|
| H3K27me3 (IF) | AR assay | Expression analysis | Other | |||
| Muotri (Marchetto et al., | hiPSCs – absent | hiPSCs – absent | hiPSCs – N/A | hiPSCs – biallelic | Pre-XCI* | |
| Neurons – present | Neurons – present | Neurons – extreme skewing | Neurons – monoallelic | |||
| Ellis (Cheung et al., | hiPSCs – mix | hiPSCs – mix | hiPSCs – extreme skewing | hiPSCs – monoallelic | Post-XCI | |
| Neurons – N/A | Neurons – N/A | Neurons – extreme skewing | Neurons – monoallelic | |||
| Renieri (Amenduni et al., | hiPSCs – N/A | hiPSCs – N/A | hiPSCs – extreme skewing | hiPSCs – monoallelic | Post-XCI | |
| Neurons – N/A | Neurons – N/A | Neurons – N/A | Neurons – N/A | |||
| Park (Kim et al., | hiPSCs – N/A | hiPSCs – absent (pre-XC)/present (post-XCI) | hiPSCs – N/A | hiPSCs – biallelic (pre-XC)/monoallelic (post-XCI) | hiPSCs – EZH2 (qRT-PCR) – low (pre-XCI)/high (post-XCI) | Pre- and post-XCI |
| Neurons – N/A | Neurons – N/A | Neurons – N/A | Neurons – N/A | |||
| Colman (Pomp et al., | hiPSCs – present | hiPSCs – N/A | hiPSCs – N/A | hiPSCs – monoallelic | Post-XCI** | |
| Neurons – N/A | Neurons – N/A | Neurons – N/A | Neurons – N/A | |||
| Chang (Ananiev et al., | hiPSCs – N/A | hiPSCs – N/A | hiPSCs – extreme skewing | hiPSCs – monoallelic | hiPSCs – | Post-XCI |
| Neurons – N/A | Neurons – N/A | Neurons (progenitors) – extreme skewing | Neurons – monoallelic | |||
*Muotri and colleagues isolated both pre- and post-XCI RTT-hiPSCs but focused on the former. **Colman and colleagues were able to isolate pre-XCI RTT-hiPSCs after naïve conversion. N/A, experiment not performed.
Commonly used techniques to evaluate XCI status in hPSCs.
| Method | Description | Advantages and disadvantages |
|---|---|---|
| Its absence (in hPSCs) is not directly correlated with the XCI status. | ||
| Chromatin marks and mediators | Repressive chromatin marks (H3K27me3, H4K20me1, MacroH2A) and their mediators (EZH2, EED) accumulate on the Xi during XCI. These marks can be detected via IF and appear as a punctate signal on the Xi. | Its absence (in hPSCs) is not directly correlated with XCI status. |
| AR assay | The X-linked | Allows XCI skewing to be calculated. Does not read out the unmethylated (active) X-chromosome. Only a single locus (Xq12) is being measured and may not reflect the entire X-chromosome. Requires polymorphism at the |
| Allele-specific expression analysis | Determine the expression of the gene of interest in an allele-specific manner. This can be done at a population level via direct sequencing of cDNA or qRT-PCR using allele-specific primers. This can also be done at a single cell level via antibodies (IF) or probes (RNA-FISH) that can distinguish WT and mutant proteins or transcripts, respectively. | Functional read out of XCI. Only a single locus is being measured and may not reflect entire X-chromosome. |
| Functional read out of XCI. Allows global transcription to be assessed. May not detect small scale reactivation of X-linked genes. Conclusion of Xi presence is based on absence of signal. | ||
| X-chromosome wide expression analysis | Determines the expression status of the entire set of genes on the X-chromosome. | Functional read out of XCI. Visualize transcriptional activity of entire set of X-linked genes. Allows identification of three classes of hPSCs – pre-XCI, post-XCI, and partial-XCI. |